Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Buqué, Aitziber ^a,b,c,d,e   Bloy, Norma ^a,b,c,d,e   Aranda, Fernando ^f   Cremer, Isabelle ^a,b,c,d   Eggermont, Alexander ^e   Fridman, Wolf Hervé ^a,b,c,d   Fucikova, Jitka ^g,h   Galon, Jérôme ^a,b,c,d   Spisek, Radek ^g,h   Tartour, Eric ^b,i,j   Zitvogel, Laurence ^a,e   Kroemer, Guido ^{a,b,c,d,e,j,k}   Galluzzi, Lorenzo ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g Sotio   (Czech Republic)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Adenosine; IDO1; myeloid derived suppressor cells; PGE2; Tregs; tumor associated macrophages

Indexed keywords

5' NUCLEOTIDASE; ACETYLSALICYLIC ACID; ARGININE; BALIXAFORTIDE; CD39 ANTIGEN; CELECOXIB; CHECKPOINT KINASE INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; DOCETAXEL; EPACADOSTAT; GALUNISERTIB; IMATINIB; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; IPILIMUMAB; JANUS KINASE 1; KYNURENINASE; MARAVIROC; MESOTHELIN; N [4 [(2 AMINO 3 CHLORO 4 PYRIDINYL)OXY] 3 FLUOROPHENYL] 4 ETHOXY 1 (4 FLUOROPHENYL) 2(1H) OXONICOTINAMIDE; PEMBROLIZUMAB; PF 4136309; PLERIXAFOR; PROSTAGLANDIN E2; PURINERGIC P2Y RECEPTOR; SIPULEUCEL T; TADALAFIL; TOLL LIKE RECEPTOR 3; TRYPTOPHAN; UNINDEXED DRUG;

BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOID CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84969627158     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1149674     Document Type: Review

References (370)

1. M.M.Mueller, N.E.Fusenig. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4:839-49; PMID:15516957; 10.1038/nrc1477
2. A.Albini, F.Tosetti, V.W.Li, D.M.Noonan, W.W.Li. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012; 9:498-509; PMID:22850752; 10.1038/nrclinonc.2012.120
3. W.H.Fridman, F.Pages, C.Sautes-Fridman, J.Galon. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; 10.1038/nrc3245
4. A.Albini, M.B.Sporn. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7:139-47; PMID:17218951; 10.1038/nrc2067
5. C.Holohan, S.Van Schaeybroeck, D.B.Longley, P.G.Johnston. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26; PMID:24060863; 10.1038/nrc3599
6. D.Di Mitri, A.Toso, A.Alimonti. Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors. Oncoimmunology 2015; 4:e988473; PMID:26405613; 10.4161/2162402X.2014.988473
7. W.H.Fridman, J.Galon, F.Pages, E.Tartour, C.Sautes-Fridman, G.Kroemer. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71:5601-5; PMID:21846822; 10.1158/0008-5472.CAN-11-1316
8. T.F.Gajewski, H.Schreiber, Y.X.Fu. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; 10.1038/ni.2703
9. C.Murdoch, M.Muthana, S.B.Coffelt, C.E.Lewis. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-31; PMID:18633355; 10.1038/nrc2444
10. E.P.Tjin, R.M.Luiten. Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients. Oncoimmunology 2014; 3:e954862; PMID:25941603; 10.4161/21624011.2014.954862
11. Y.Issa-Nummer, S.Loibl, G.von Minckwitz, C.Denkert. Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. Oncoimmunology 2014; 3:e27926; PMID:25340002; 10.4161/onci.27926
12. M.Semeraro, S.Rusakiewicz, L.Zitvogel, G.Kroemer. Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. Oncoimmunology 2015; 4:e1042202; PMID:26451315; 10.1080/2162402X.2015.1042202
13. R.D.Schreiber, L.J.Old, M.J.Smyth. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; 10.1126/science.1203486
14. G.Kroemer, L.Galluzzi, L.Zitvogel, W.H.Fridman. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology 2015; 4:e1058597; PMID:26140250; 10.1080/2162402X.2015.1058597
15. A.Kallies T cell immunosurveillance controls B lymphoma development. Oncoimmunology 2014; 3:e28697; PMID:25050223; 10.4161/onci.28697
16. L.Zitvogel, A.Tesniere, G.Kroemer. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; 10.1038/nri1936
17. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; 10.1038/ni1102-991
18. H.Matsushita, M.D.Vesely, D.C.Koboldt, C.G.Rickert, R.Uppaluri, V.J.Magrini, C.D.Arthur, J.M.White, Y.S.Chen, L.K.Shea et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; 10.1038/nature10755
19. L.Danelli, B.Frossi, C.E.Pucillo. Mast cell/MDSC a liaison immunosuppressive for tumor microenvironment. Oncoimmunology 2015; 4:e1001232; PMID:26137400; 10.1080/2162402X.2014.1001232
20. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; 10.1038/nri2506
21. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; 10.1038/nri3175
22. A.A.Wu, V.Drake, H.S.Huang, S.Chiu, L.Zheng. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015; 4:e1016700; PMID:26140242; 10.1080/2162402X.2015.1016700
23. V.G.Pillarisetty. The pancreatic cancer microenvironment: an immunologic battleground. Oncoimmunology 2014; 3:e950171; PMID:25610740; 10.4161/21624011.2014.950171
24. L.Senovilla, E.Vacchelli, J.Galon, S.Adjemian, A.Eggermont, W.H.Fridman, C.Sautès-Fridman, Y.Ma, E.Tartour, L.Zitvogel et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; 10.4161/onci.22009
25. C.Tripathi, B.N.Tewari, R.K.Kanchan, K.S.Baghel, N.Nautiyal, R.Shrivastava, H.Kaur, M.L.Bhatt, S.Bhadauria. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 2014; 5:5350-68; PMID:25051364; 10.18632/oncotarget.2110
26. P.Balermpas, F.Rodel, C.Weiss, C.Rodel, E.Fokas. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014; 3:e27403; PMID:24711959; 10.4161/onci.27403
27. L.Galluzzi, A.Buque, O.Kepp, L.Zitvogel, G.Kroemer. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 2015; 28:690-714; PMID:26678337; 10.1016/j.ccell.2015.10.012
28. E.B.Golden, L.Apetoh. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015; 25:11-7; PMID:25481261; 10.1016/j.semradonc.2014.07.005
29. A.M.Grimaldi, E.Simeone, D.Giannarelli, P.Muto, S.Falivene, V.Borzillo, F.M.Giugliano, F.Sandomenico, A.Petrillo, M.Curvietto et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; 10.4161/onci.28780
30. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; 10.1016/j.immuni.2013.06.014
31. C.Twyman-Saint Victor, A.J.Rech, A.Maity, R.Rengan, K.E.Pauken, E.Stelekati, J.L.Benci, B.Xu, H.Dada, P.M.Odorizzi et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; 10.1038/nature14292
32. E.B.Golden, D.Frances, I.Pellicciotta, S.Demaria, M.Helen Barcellos-Hoff, S.C.Formenti. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; 10.4161/onci.28518
33. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; PMID:25941606; 10.4161/21624011.2014.954929
34. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; 10.4161/onci.29179
35. H.von Boehmer, C.Daniel. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013; 12:51-63; PMID:23274471; 10.1038/nrd3683
36. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; 10.1038/nrc3239
37. J.L.Adams, J.Smothers, R.Srinivasan, A.Hoos. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 2015; 14:603-22; PMID:26228631; 10.1038/nrd4596
38. N.Hardwick, V.Chung, M.Cristea, J.D.Ellenhorn, D.J.Diamond. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology 2014; 3:e958949; PMID:25941580; 10.4161/21624011.2014.958949
39. E.J.Hennessy, A.E.Parker, L.A.O'Neill. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9:293-307; PMID:20380038; 10.1038/nrd3203
40. L.A.O'Neill, D.Golenbock, A.G.Bowie. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013; 13:453-60; PMID:23681101; 10.1038/nri3446
41. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; 10.4161/onci.29030
42. I.Melero, S.Hervas-Stubbs, M.Glennie, D.M.Pardoll, L.Chen. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:17251916; 10.1038/nrc2051
43. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; 10.4161/onci.27297
44. A.Buque, N.Bloy, F.Aranda, F.Castoldi, A.Eggermont, I.Cremer, W.H.Fridman, J.Fucikova, J.Galon, A.Marabelle et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4:e1008814; PMID:26137403; 10.1080/2162402X.2015.1008814
45. L.Apetoh, M.J.Smyth, C.G.Drake, J.P.Abastado, R.N.Apte, M.Ayyoub, J.Y.Blay, M.Bonneville, L.H.Butterfield, A.Caignard et al. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology 2015; 4:e998538; PMID:26137416; 10.1080/2162402X.2014.998538
46. P.Sharma, J.P.Allison. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; 10.1126/science.aaa8172
47. P.Sharma, J.P.Allison. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14; PMID:25860605; 10.1016/j.cell.2015.03.030
48. L.Galluzzi, G.Kroemer, A.Eggermont. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3:e967147; PMID:25941597; 10.4161/21624011.2014.967147
49. T.Voron, O.Colussi, E.Marcheteau, S.Pernot, M.Nizard, A.L.Pointet, S.Latreche, S.Bergaya, N.Benhamouda, C.Tanchot et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212:139-48; PMID:25601652; 10.1084/jem.20140559
50. E.Vacchelli, J.Pol, N.Bloy, A.Eggermont, I.Cremer, W.H.Fridman, J.Galon, A.Marabelle, H.Kohrt, L.Zitvogel et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4:e985940; PMID:25949870; 10.4161/2162402X.2014.985940
51. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; 10.4161/21624011.2014.955691
52. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; 10.1146/annurev-immunol-032712-100008
53. S.A.Gujar, D.Clements, P.W.Lee. Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; 10.4161/onci.27622
54. J.Wu, D.J.Waxman. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 T-cell responses and immune memory. Oncoimmunology 2015; 4:e1005521; PMID:26137402; 10.1080/2162402X.2015.1005521
55. O.Draghiciu, J.Lubbers, H.W.Nijman, T.Daemen. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 2015; 4:e954829; PMID:25949858; 10.4161/21624011.2014.954829
56. M.Xu, M.Liu, X.Du, S.Li, H.Li, X.Li, Y.Li, Y.Wang, Z.Qin, Y.X.Fu et al. Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. J Immunol 2015; 194:4997-5006; PMID:25876763; 10.4049/jimmunol.1402603
57. A.M.Dudek, A.D.Garg, D.V.Krysko, D.De Ruysscher, P.Agostinis. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24:319-33; PMID:23391812; 10.1016/j.cytogfr.2013.01.005
58. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; 10.1038/nrc3380
59. J.Pol, E.Vacchelli, F.Aranda, F.Castoldi, A.Eggermont, I.Cremer, C.Sautès-Fridman, J.Fucikova, J.Galon, R.Spisek et al. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015; 4:e1008866; PMID:26137404; 10.1080/2162402X.2015.1008866
60. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; 10.4161/onci.27878
61. R.K.Shrimali, Z.Yu, M.R.Theoret, D.Chinnasamy, N.P.Restifo, S.A.Rosenberg. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; 10.1158/0008-5472.CAN-10-0153
62. S.Lob, A.Konigsrainer, H.G.Rammensee, G.Opelz, P.Terness. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9:445-52; PMID:19461669; 10.1038/nrc2639
63. J.R.Moffett, M.A.Namboodiri. Tryptophan and the immune response. Immunol Cell Biol 2003; 81:247-65; PMID:12848846; 10.1046/j.1440-1711.2003.t01-1-01177.x
64. V.Vonka, Z.Humlova, H.Klamova, L.Kujovska-Krcmova, M.Petrackova, E.Hamsikova, M.Krmencikova-Fliegl, M.Duskova, Z.Roth. Kynurenine and uric acid levels in chronic myeloid leukemia patients. Oncoimmunology 2015; 4:e992646; PMID:25949913; 10.4161/2162402X.2014.992646
65. C.Guillonneau, M.Hill, F.X.Hubert, E.Chiffoleau, C.Herve, X.L.Li, M.Heslan, C.Usal, L.Tesson, S.Ménoret et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:1096-106; PMID:17404623; 10.1172/JCI28801
66. P.Hwu, M.X.Du, R.Lapointe, M.Do, M.W.Taylor, H.A.Young. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164:3596-9; PMID:10725715; 10.4049/jimmunol.164.7.3596
67. P.Giannoni, G.Pietra, G.Travaini, R.Quarto, G.Shyti, R.Benelli, L.Ottaggio, M.C.Mingari, S.Zupo, G.Cutrona et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 2014; 99:1078-87; PMID:24561793; 10.3324/haematol.2013.091405
68. R.Rani, M.B.Jordan, S.Divanovic, D.R.Herbert. IFN-gamma-driven IDO production from macrophages protects IL-4Ralpha-deficient mice against lethality during Schistosoma mansoni infection. Am J Pathol 2012; 180:2001-8; PMID:22426339; 10.1016/j.ajpath.2012.01.013
69. R.Potula, L.Poluektova, B.Knipe, J.Chrastil, D.Heilman, H.Dou, O.Takikawa, D.H.Munn, H.E.Gendelman, Y.Persidsky. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005; 106:2382-90; PMID:15961516; 10.1182/blood-2005-04-1403
70. J.Yu, Y.Wang, F.Yan, P.Zhang, H.Li, H.Zhao, C.Yan, F.Yan, X.Ren. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol 2014; 193:2574-86; PMID:25063873; 10.4049/jimmunol.1400833
71. N.Vigneron, N.van Baren, B.J.Van den Eynde. Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance. Oncoimmunology 2015; 4:e1003012; PMID:26155395; 10.1080/2162402X.2014.1003012
72. D.H.Munn, E.Shafizadeh, J.T.Attwood, I.Bondarev, A.Pashine, A.L.Mellor. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72; PMID:10224276; 10.1084/jem.189.9.1363
73. D.H.Munn, M.Zhou, J.T.Attwood, I.Bondarev, S.J.Conway, B.Marshall, C.Brown, A.L.Mellor. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-3; PMID:9712583; 10.1126/science.281.5380.1191
74. C.Uyttenhove, L.Pilotte, I.Theate, V.Stroobant, D.Colau, N.Parmentier, T.Boon, B.J.Van den Eynde. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; 10.1038/nm934
75. F.Fallarino, U.Grohmann, C.Vacca, C.Orabona, A.Spreca, M.C.Fioretti, P.Puccetti. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003; 527:183-90; PMID:15206731; 10.1007/978-1-4615-0135-0_21
76. T.Hayashi, J.H.Mo, X.Gong, C.Rossetto, A.Jang, L.Beck, G.I.Elliott, I.Kufareva, R.Abagyan, D.H.Broide et al. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci U S A 2007; 104:18619-24; PMID:18003900; 10.1073/pnas.0709261104
77. A.L.Mellor, B.Baban, P.Chandler, B.Marshall, K.Jhaver, A.Hansen, P.A.Koni, M.Iwashima, D.H.Munn. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171:1652-5; PMID:12902462; 10.4049/jimmunol.171.4.1652
78. B.Baban, A.M.Hansen, P.R.Chandler, A.Manlapat, A.Bingaman, D.J.Kahler, D.H.Munn, A.L.Mellor. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17:909-19; PMID:15967784; 10.1093/intimm/dxh271
79. A.Molano, P.A.Illarionov, G.S.Besra, C.Putterman, S.A.Porcelli. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 2008; 117:81-90; PMID:18272236; 10.1016/j.imlet.2007.12.013
80. S.B.Adikari, H.Lian, H.Link, Y.M.Huang, B.G.Xiao. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004; 138:230-6; PMID:15498031; 10.1111/j.1365-2249.2004.02585.x
81. D.H.Munn, M.D.Sharma, J.R.Lee, K.G.Jhaver, T.S.Johnson, D.B.Keskin, B.Marshall, P.Chandler, S.J.Antonia, R.Burgess et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297:1867-70; PMID:12228717; 10.1126/science.1073514
82. F.Fallarino, C.Orabona, C.Vacca, R.Bianchi, S.Gizzi, C.Asselin-Paturel, M.C.Fioretti, G.Trinchieri, U.Grohmann, P.Puccetti. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int Immunol 2005; 17:1429-38; PMID:16172135; 10.1093/intimm/dxh321
83. F.Fallarino, C.Asselin-Paturel, C.Vacca, R.Bianchi, S.Gizzi, M.C.Fioretti, G.Trinchieri, U.Grohmann, P.Puccetti. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004; 173:3748-54; PMID:15356121; 10.4049/jimmunol.173.6.3748
84. M.D.Sharma, B.Baban, P.Chandler, D.Y.Hou, N.Singh, H.Yagita, M.Azuma, B.R.Blazar, A.L.Mellor, D.H.Munn. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; 10.1172/JCI31911
85. R.A.Derks, E.Jankowska-Gan, Q.Xu, W.J.Burlingham. Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol 2007; 179:3443-51; PMID:17785778; 10.4049/jimmunol.179.6.3443
86. D.H.Munn, M.D.Sharma, D.Hou, B.Baban, J.R.Lee, S.J.Antonia, J.L.Messina, P.Chandler, P.A.Koni, A.L.Mellor. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90; PMID:15254595; 10.1172/JCI200421583
87. E.Vacchelli, F.Aranda, A.Eggermont, C.Sautes-Fridman, E.Tartour, E.P.Kennedy, M.Platten, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014; 3:e957994; PMID:25941578; 10.4161/21624011.2014.957994
88. D.H.Munn, A.L.Mellor. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34:137-43; PMID:23103127; 10.1016/j.it.2012.10.001
89. V.P.Balachandran, M.J.Cavnar, S.Zeng, Z.M.Bamboat, L.M.Ocuin, H.Obaid, E.C.Sorenson, R.Popow, C.Ariyan, F.Rossi et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; 10.1038/nm.2438
90. G.Kroemer, L.Senovilla, L.Galluzzi, F.Andre, L.Zitvogel. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015; 21:1128-38; PMID:26444637; 10.1038/nm.3944
91. A.Quintas-Cardama, H.Kantarjian, J.Cortes. Imatinib and beyond–exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009; 6:535-43; PMID:19652654; 10.1038/nrclinonc.2009.112
92. R.Capdeville, E.Buchdunger, J.Zimmermann, A.Matter. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502; PMID:12120256; 10.1038/nrd839
93. L.Zhai, S.Spranger, D.C.Binder, G.Gritsina, K.L.Lauing, F.J.Giles, D.A.Wainwright. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res 2015; 21:5427-33; PMID:26519060; 10.1158/1078-0432.CCR-15-0420
94. F.Qian, J.Liao, J.Villella, R.Edwards, P.Kalinski, S.Lele, P.Shrikant, K.Odunsi. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother 2012; 61:2013-20; PMID:22527253; 10.1007/s00262-012-1265-x
95. A.J.Muller, J.B.DuHadaway, P.S.Donover, E.Sutanto-Ward, G.C.Prendergast. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; PMID:15711557; 10.1038/nm1196
96. D.Y.Hou, A.J.Muller, M.D.Sharma, J.DuHadaway, T.Banerjee, M.Johnson, A.L.Mellor, G.C.Prendergast, D.H.Munn. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801; PMID:17234791; 10.1158/0008-5472.CAN-06-2925
97. R.B.Holmgaard, D.Zamarin, D.H.Munn, J.D.Wolchok, J.P.Allison. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23752227; 10.1084/jem.20130066
98. D.A.Wainwright, A.L.Chang, M.Dey, I.V.Balyasnikova, C.K.Kim, A.Tobias, Y.Cheng, J.W.Kim, J.Qiao, L.Zhang et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; 10.1158/1078-0432.CCR-14-0514
99. D.A.Wainwright, M.S.Lesniak. Menage a trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma. Oncoimmunology 2014; 3:e28927; PMID:25057450; 10.4161/onci.28927
100. R.Metz, J.B.Duhadaway, U.Kamasani, L.Laury-Kleintop, A.J.Muller, G.C.Prendergast. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7082-7; PMID:17671174; 10.1158/0008-5472.CAN-07-1872
101. S.G.Cady, M.Sono. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991; 291:326-33; PMID:1952947; 10.1016/0003-9861(91)90142-6
102. H.H.Soliman, E.Jackson, T.Neuger, E.C.Dees, R.D.Harvey, H.Han, R.Ismail-Khan, S.Minton, N.N.Vahanian, C.Link et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 2014; 5:8136-46; PMID:25327557; 10.18632/oncotarget.2357
103. E.Jackson, E.C.Dees, J.S.Kauh, R.D.Harvey, A.Neuger, R.Lush, J.S.Antonia, S.E.Minton, R.Ismail-Khan, H.S.Han et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. J Clin Oncol 2013; 31:abstr 3026; PMID:23857967; 10.1200/JCO.2012.47.1235
104. H.Colman, F.Mott, A.I.Spira, T.S.Johnson, Y.Zakharia, N.N.Vahanian, C.J.Link, E.P.Kennedy, R.F.Sadek, D.Munn et al. A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component. ASCO Meeting Abstracts 2015; 33:2070
105. H.H.Soliman, S.E.Minton, R.Ismail-Khan, H.S.Han, W.Janssen, N.N.Vahanian et al. A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J Clin Oncol 2013; 31:abstr 3069; 10.1200/JCO.2013.49.9202
106. Y.Zakharia, T.S.Johnson, H.Colman, N.N.Vahanian, C.J.Link, E.Kennedy et al. A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors. J Clin Oncol 2014; 32:abstr TPS2107
107. G.G.Jha, J.S.Miller. A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. ASCO Meeting Abstracts 2014; 32:TPS5111
108. H.H.Soliman, S.E.Minton, R.Ismail-Khan, H.S.Han, N.N.Vahanian, W.J.Ramsey et al. A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer. J Clin Oncol 2014; 32:abstr TPS3124
109. E.Kennedy, G.R.Rossi, N.N.Vahanian, C.J.Link. Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. ASCO Meeting Abstracts 2014; 32:TPS9117
110. H.K.Koblish, M.J.Hansbury, K.J.Bowman, G.Yang, C.L.Neilan, P.J.Haley, T.C.Burn, P.Waeltz, R.B.Sparks, E.W.Yue et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9:489-98; PMID:20124451; 10.1158/1535-7163.MCT-09-0628
111. X.Liu, N.Shin, H.K.Koblish, G.Yang, Q.Wang, K.Wang, L.Leffet, M.J.Hansbury, B.Thomas, M.Rupar et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115:3520-30; PMID:20197554; 10.1182/blood-2009-09-246124
112. M.Li, A.R.Bolduc, M.N.Hoda, D.N.Gamble, S.B.Dolisca, A.K.Bolduc, K.Hoang, C.Ashley, D.McCall, A.M.Rojiani et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer 2014; 2:21; PMID:25054064; 10.1186/2051-1426-2-21
113. M.R.Mautino, F.A.Jaipuri, J.Waldo, S.Kumar, J.Adams, C.Van Allen et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res 2013; 73:491; 10.1158/1538-7445.AM2013-491
114. G.L.Beatty, P.J.O'Dwyer, J.Clark, J.G.Shi, R.C.Newton, R.Schaub et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. ASCO Meeting Abstracts 2013; 31:3025
115. R.C.Newton, P.A.Scherle, K.Bowman, X.Liu, G.L.Beatty, P.J.O'Dwyer et al. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. ASCO Meeting Abstracts 2012; 30:2500
116. G.T.Gibney, O.Hamid, T.C.Gangadhar, J.Lutzky, A.J.Olszanski, T.Gajewski et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. ASCO Meeting Abstracts 2014; 32:3010
117. M.Tanaka, X.Li, H.Hikawa, T.Suzuki, K.Tsutsumi, M.Sato, O.Takikawa, H.Suzuki, Y.Yokoyama. Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorg Med Chem 2013; 21:1159-65; PMID:23337802; 10.1016/j.bmc.2012.12.028
118. P.Gaspari, T.Banerjee, W.P.Malachowski, A.J.Muller, G.C.Prendergast, J.DuHadaway, S.Bennett, A.M.Donovan. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006; 49:684-92; PMID:16420054; 10.1021/jm0508888
119. T.Banerjee, J.B.Duhadaway, P.Gaspari, E.Sutanto-Ward, D.H.Munn, A.L.Mellor, W.P.Malachowski, G.C.Prendergast, A.J.Muller. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008; 27:2851-7; PMID:18026137; 10.1038/sj.onc.1210939
120. A.Pereira, E.Vottero, M.Roberge, A.G.Mauk, R.J.Andersen. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 2006; 69:1496-9; PMID:17067170; 10.1021/np060111x
121. S.Kumar, W.P.Malachowski, J.B.DuHadaway, J.M.LaLonde, P.J.Carroll, D.Jaller, R.Metz, G.C.Prendergast, A.J.Muller. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008; 51:1706-18; PMID:18318466; 10.1021/jm7014155
122. M.Volgraf, J.P.Lumb, H.C.Brastianos, G.Carr, M.K.Chung, M.Munzel, A.G.Mauk, R.J.Andersen, D.Trauner. Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol 2008; 4:535-7; PMID:18677305; 10.1038/nchembio.107
123. H.C.Brastianos, E.Vottero, B.O.Patrick, R.Van Soest, T.Matainaho, A.G.Mauk, R.J.Andersen. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 2006; 128:16046-7; PMID:17165752; 10.1021/ja067211+
124. L.Pilotte, P.Larrieu, V.Stroobant, D.Colau, E.Dolusic, R.Frederick, E.De Plaen, C.Uyttenhove, J.Wouters, B.Masereel et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 2012; 109:2497-502; PMID:22308364; 10.1073/pnas.1113873109
125. W.G.Junger. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011; 11:201-12; PMID:21331080; 10.1038/nri2938
126. M.Michaud, X.Xie, J.M.Bravo-San Pedro, L.Zitvogel, E.White, G.Kroemer. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology 2014; 3:e944047; PMID:25610726; 10.4161/21624011.2014.944047
127. I.Adkins, J.Fucikova, A.D.Garg, P.Agostinis, R.Spisek. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014; 3:e968434; PMID:25964865; 10.4161/21624011.2014.968434
128. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret, K.Steegh et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; 10.1016/j.immuni.2013.03.003
129. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; 10.1038/nm.2028
130. L.Antonioli, P.Pacher, E.S.Vizi, G.Hasko. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19:355-67; PMID:23601906; 10.1016/j.molmed.2013.03.005
131. P.A.Beavis, C.Y.Slaney, N.Milenkovski, M.A.Henderson, S.Loi, J.Stagg, M.H.Kershaw, P.K.Darcy. CD73: A potential biomarker for anti-PD-1 therapy. Oncoimmunology 2015; 4:e1046675; PMID:26451321; 10.1080/2162402X.2015.1046675
132. L.Antonioli, C.Blandizzi, P.Pacher, G.Hasko. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13:842-57; PMID:24226193; 10.1038/nrc3613
133. S.Deaglio, K.M.Dwyer, W.Gao, D.Friedman, A.Usheva, A.Erat, J.F.Chen, K.Enjyoji, J.Linden, M.Oukka et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65; PMID:17502665; 10.1084/jem.20062512
134. C.Cekic, Y.J.Day, D.Sag, J.Linden. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 2014; 74:7250-9; PMID:25377469; 10.1158/0008-5472.CAN-13-3583
135. S.P.Hilchey, J.J.Kobie, M.R.Cochran, S.Secor-Socha, J.C.Wang, O.Hyrien, W.R.Burack, T.R.Mosmann, S.A.Quataert, S.H.Bernstein. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol 2009; 183:6157-66; PMID:19864600; 10.4049/jimmunol.0900475
136. A.Ohta, R.Kini, A.Ohta, M.Subramanian, M.Madasu, M.Sitkovsky. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012; 3:190; PMID:22783261; 10.3389/fimmu.2012.00190
137. L.S.Bergamin, E.Braganhol, F.Figueiro, E.A.Casali, R.F.Zanin, J.Sevigny, A.M.Battastini. Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium. J Cell Biochem 2015; 116:721-9; PMID:25546398; 10.1002/jcb.25018
138. B.Csoka, Z.Selmeczy, B.Koscso, Z.H.Nemeth, P.Pacher, P.J.Murray, D.Kepka-Lenhart, S.M.MorrisJr, W.C.Gause, S.J.Leibovich et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 2012; 26:376-86; PMID:21926236; 10.1096/fj.11-190934
139. S.Ryzhov, S.V.Novitskiy, A.E.Goldstein, A.Biktasova, M.R.Blackburn, I.Biaggioni, M.M.Dikov, I.Feoktistov. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 2011; 187:6120-9; PMID:22039302; 10.4049/jimmunol.1101225
140. S.Morello, L.Miele. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. Oncoimmunology 2014; 3:e27989; PMID:25101221; 10.4161/onci.27989
141. S.V.Novitskiy, S.Ryzhov, R.Zaynagetdinov, A.E.Goldstein, Y.Huang, O.Y.Tikhomirov, M.R.Blackburn, I.Biaggioni, D.P.Carbone, I.Feoktistov et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008; 112:1822-31; PMID:18559975; 10.1182/blood-2008-02-136325
142. S.Sheth, R.Brito, D.Mukherjea, L.P.Rybak, V.Ramkumar. Adenosine receptors: expression, function and regulation. Int J Mol Sci 2014; 15:2024-52; PMID:24477263; 10.3390/ijms15022024
143. G.Bianchi, M.Vuerich, P.Pellegatti, D.Marimpietri, L.Emionite, I.Marigo, V.Bronte, F.Di Virgilio, V.Pistoia, L.Raffaghello. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis 2014; 5:e1135; PMID:24651438; 10.1038/cddis.2014.109
144. S.Chadet, F.Ivanes, L.Benoist, C.Salmon-Gandonniere, R.Guibon, F.Velge-Roussel, D.Babuty, C.Baron, S.Roger, D.Angoulvant. Hypoxia/Reoxygenation Inhibits P2Y11 Receptor Expression and Its Immunosuppressive Activity in Human Dendritic Cells. J Immunol 2015; 195:651-60; PMID:26078273; 10.4049/jimmunol.1500197
145. M.J.Smyth, S.F.Ngiow, A.Ribas, M.W.Teng. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016; 13:143-58; PMID:26598942; 10.1038/nrclinonc.2015.209
146. N.Bonnefoy, J.Bastid, G.Alberici, A.Bensussan, J.F.Eliaou. CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. Oncoimmunology 2015; 4:e1003015; PMID:26155397; 10.1080/2162402X.2014.1003015
147. Y.Baqi, S.Weyler, J.Iqbal, H.Zimmermann, C.E.Muller. Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 2009; 5:91-106; PMID:18528783; 10.1007/s11302-008-9103-5
148. J.Lecka, I.Gillerman, M.Fausther, M.Salem, M.N.Munkonda, J.P.Brosseau, C.Cadot, M.Martín-Satué, P.d'Orléans-Juste, E.Rousseau et al. 8-BuS-ATP derivatives as specific NTPDase1 inhibitors. Br J Pharmacol 2013; 169:179-96; PMID:23425137; 10.1111/bph.12135
149. K.Knapp, M.Zebisch, J.Pippel, A.El-Tayeb, C.E.Muller, N.Strater. Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 2012; 20:2161-73; PMID:23142347; 10.1016/j.str.2012.10.001
150. M.Krasteva, A.Barth. Structures of the Ca2+-ATPase complexes with ATP, AMPPCP and AMPPNP. An FTIR study. Biochim Biophys Acta 2007; 1767:114-23; PMID:17157262; 10.1016/j.bbabio.2006.11.003
151. S.Bhattarai, M.Freundlieb, J.Pippel, A.Meyer, A.Abdelrahman, A.Fiene, S.Y.Lee, H.Zimmermann, G.G.Yegutkin, N.Sträter et al. alpha,beta-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors. J Med Chem 2015; 58:6248-63; PMID:26147331; 10.1021/acs.jmedchem.5b00802
152. G.Forte, R.Sorrentino, A.Montinaro, A.Luciano, I.M.Adcock, P.Maiolino, C.Arra, C.Cicala, A.Pinto, S.Morello. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 2012; 189:2226-33; PMID:22826317; 10.4049/jimmunol.1200744
153. P.A.Beavis, U.Divisekera, C.Paget, M.T.Chow, L.B.John, C.Devaud, K.Dwyer, J.Stagg, M.J.Smyth, P.K.Darcy. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 2013; 110:14711-6; PMID:23964122; 10.1073/pnas.1308209110
154. D.Jin, J.Fan, L.Wang, L.F.Thompson, A.Liu, B.J.Daniel, T.Shin, T.J.Curiel, B.Zhang. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010; 70:2245-55; PMID:20179192; 10.1158/0008-5472.CAN-09-3109
155. J.Stagg, U.Divisekera, H.Duret, T.Sparwasser, M.W.Teng, P.K.Darcy, M.J.Smyth. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011; 71:2892-900; PMID:21292811; 10.1158/0008-5472.CAN-10-4246
156. G.G.Yegutkin, F.Marttila-Ichihara, M.Karikoski, J.Niemela, J.P.Laurila, K.Elima, S.Jalkanen, M.Salmi. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41:1231-41; PMID:21469131; 10.1002/eji.201041292
157. M.Michaud, I.Martins, A.Q.Sukkurwala, S.Adjemian, Y.Ma, P.Pellegatti, S.Shen, O.Kepp, M.Scoazec, G.Mignot et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; 10.1126/science.1208347
158. L.Wang, J.Fan, L.F.Thompson, Y.Zhang, T.Shin, T.J.Curiel, B.Zhang. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121:2371-82; PMID:21537079; 10.1172/JCI45559
159. E.Ntantie, P.Gonyo, E.L.Lorimer, A.D.Hauser, N.Schuld, D.McAllister, B.Kalyanaraman, M.B.Dwinell, J.A.Auchampach, C.L.Williams. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal 2013; 6:ra39; PMID:23716716; 10.1126/scisignal.2003374.
160. X.Zhou, X.Zhi, P.Zhou, S.Chen, F.Zhao, Z.Shao, Z.Ou, L.Yin. Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 2007; 17:1341-6; PMID:17487388; 10.3892/or.17.6.1341
161. J.Bastid, A.Regairaz, N.Bonnefoy, C.Dejou, J.Giustiniani, C.Laheurte, S.Cochaud, E.Laprevotte, E.Funck-Brentano, P.Hemon et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015; 3:254-65; PMID:25403716; 10.1158/2326-6066.CIR-14-0018
162. A.Clayton, S.Al-Taei, J.Webber, M.D.Mason, Z.Tabi. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011; 187:676-83; PMID:21677139; 10.4049/jimmunol.1003884
163. R.Iannone, L.Miele, P.Maiolino, A.Pinto, S.Morello. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 2014; 4:172-81; PMID:24660106
164. M.A.Villalona-Calero, M.G.Wientjes, G.A.Otterson, S.Kanter, D.Young, A.J.Murgo, B.Fischer, C.DeHoff, D.Chen, T.K.Yeh et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 9:3303-11; PMID:12960116
165. M.A.Villalona-Calero, G.A.Otterson, M.G.Wientjes, F.Weber, T.Bekaii-Saab, D.Young, A.J.Murgo, R.Jensen, T.K.Yeh, Y.Wei et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol 2008; 19:1903-9; PMID:18632723; 10.1093/annonc/mdn412
166. S.George, R.Dreicer, J.J.Au, T.Shen, B.I.Rini, S.Roman, M.M.Cooney, T.Mekhail, P.Elson, G.M.Wientjes et al. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2008; 6:79-85; PMID:18824429; 10.3816/CGC.2008.n.012
167. E.T.Lam, J.L.Au, G.A.Otterson, M.Guillaume Wientjes, L.Chen, T.Shen, Y.Wei, X.Li, T.Bekaii-Saab, A.J.Murgo et al. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 66:1019-29; PMID:20107799; 10.1007/s00280-010-1252-x
168. M.B.Lustberg, S.Pant, A.S.Ruppert, T.Shen, Y.Wei, L.Chen, L.Brenner, D.Shiels, R.R.Jensen, M.Berger et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol 2012; 70:49-56; PMID:22729159; 10.1007/s00280-012-1887-x
169. S.Meis, A.Hamacher, D.Hongwiset, C.Marzian, M.Wiese, N.Eckstein, H.D.Royer, D.Communi, J.M.Boeynaems, R.Hausmann et al. NF546 [4,4′-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-car bonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther 2010; 332:238-47; PMID:19815812; 10.1124/jpet.109.157750
170. D.Mittal, A.Young, K.Stannard, M.Yong, M.W.Teng, B.Allard, J.Stagg, M.J.Smyth. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 2014; 74:3652-8; PMID:24986517; 10.1158/0008-5472.CAN-14-0957
171. A.Young, D.Mittal, K.Stannard, M.Yong, M.W.Teng, B.Allard, J.Stagg, M.J.Smyth. Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. Oncoimmunology 2014; 3:e958952; PMID:25941583; 10.4161/21624011.2014.958952
172. R.J.Vorovenci, A.Antonini. The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Rev Neurother 2015; 15:1383-90; PMID:26630457; 10.1586/14737175.2015.1113131
173. P.Jenner An overview of adenosine A2A receptor antagonists in Parkinson's disease. Int Rev Neurobiol 2014; 119:71-86; PMID:25175961; 10.1016/B978-0-12-801022-8.00003-9
174. R.A.Hauser, F.Stocchi, O.Rascol, S.B.Huyck, R.Capece, T.W.Ho, P.Sklar, C.Lines, D.Michelson, D.Hewitt. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015; 72:1491-500; PMID:26523919; 10.1001/jamaneurol.2015.2268
175. S.A.Factor, K.Wolski, D.M.Togasaki, S.Huyck, M.Cantillon, T.W.Ho, R.A.Hauser, E.Pourcher. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord 2013; 28:817-20; PMID:23589371; 10.1002/mds.25395
176. J.F.Chen, H.K.Eltzschig, B.B.Fredholm. Adenosine receptors as drug targets–what are the challenges? Nat Rev Drug Discov 2013; 12:265-86; PMID:23535933; 10.1038/nrd3955
177. R.Iannone, L.Miele, P.Maiolino, A.Pinto, S.Morello. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 2013; 15:1400-9; PMID:24403862; 10.1593/neo.131748
178. W.Kaji, S.Tanaka, M.Tsukimoto, S.Kojima. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. J Toxicol Sci 2014; 39:191-8; PMID:24646699; 10.2131/jts.39.191
179. C.Sorrentino, L.Miele, A.Porta, A.Pinto, S.Morello. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget 2015; 6:27478-89; PMID:26317647; 10.18632/oncotarget.4393
180. F.Ochoa-Cortes, A.Linan-Rico, K.A.Jacobson, F.L.Christofi. Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm Bowel Dis 2014; 20:1259-87; PMID:24859298; 10.1097/MIB.0000000000000047
181. R.Polosa, M.R.Blackburn. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 2009; 30:528-35; PMID:19762093; 10.1016/j.tips.2009.07.005
182. R.V.Kalla, J.Zablocki. Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. Purinergic Signal 2009; 5:21-9; PMID:18568423; 10.1007/s11302-008-9119-x
183. A.Kaidi, D.Qualtrough, A.C.Williams, C.Paraskeva. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 2006; 66:6683-91; PMID:16818642; 10.1158/0008-5472.CAN-06-0425
184. E.A.Dennis, P.C.Norris. Eicosanoid storm in infection and inflammation. Nat Rev Immunol 2015; 15:511-23; PMID:26139350; 10.1038/nri3859
185. Q.Huang, F.Li, X.Liu, W.Li, W.Shi, F.F.Liu, B.O'Sullivan, Z.He, Y.Peng, A.C.Tan et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17:860-6; PMID:21725296; 10.1038/nm.2385
186. F.Li, Q.Huang, J.Chen, Y.Peng, D.R.Roop, J.S.Bedford, C.Y.Li. Apoptotic cells activate the “phoenix rising” pathway to promote wound healing and tissue regeneration. Sci Signal 2010; 3:ra13; PMID:20179271; 10.1126/scisignal.2000634.
187. Z.L.Li, S.B.Ye, L.Y.OuYang, H.Zhang, Y.S.Chen, J.He, Q.Y.Chen, C.N.Qian, X.S.Zhang, J.Cui et al. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology 2015; 4:e1044712; PMID:26451317; 10.1080/2162402X.2015.1044712
188. G.T.Motz, S.P.Santoro, L.P.Wang, T.Garrabrant, R.R.Lastra, I.S.Hagemann, P.Lal, M.D.Feldman, F.Benencia, G.Coukos. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20:607-15; PMID:24793239; 10.1038/nm.3541
189. S.Zelenay, A.G.van der Veen, J.P.Bottcher, K.J.Snelgrove, N.Rogers, S.E.Acton, P.Chakravarty, M.R.Girotti, R.Marais, S.A.Quezada et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015; 162:1257-70; PMID:26343581; 10.1016/j.cell.2015.08.015
190. A.J.O'Brien, J.N.Fullerton, K.A.Massey, G.Auld, G.Sewell, S.James, J.Newson, E.Karra, A.Winstanley, W.Alazawi et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20:518-23; PMID:24728410; 10.1038/nm.3516
191. D.Gonnermann, H.H.Oberg, C.Kellner, M.Peipp, S.Sebens, D.Kabelitz, D.Wesch. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against gammadelta T cell cytotoxicity. Oncoimmunology 2015; 4:e988460; PMID:25949900; 10.4161/2162402X.2014.988460
192. L.Martinet, C.Jean, G.Dietrich, J.J.Fournie, R.Poupot. PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010; 80:838-45; PMID:20470757; 10.1016/j.bcp.2010.05.002
193. D.Holt, X.Ma, N.Kundu, A.Fulton. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011; 60:1577-86; PMID:21681369; 10.1007/s00262-011-1064-9
194. Y.Mao, D.Sarhan, A.Steven, B.Seliger, R.Kiessling, A.Lundqvist. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 2014; 20:4096-106; PMID:24907113; 10.1158/1078-0432.CCR-14-0635
195. D.M.Holt, X.Ma, N.Kundu, P.D.Collin, A.M.Fulton. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35:179-88; PMID:22306906; 10.1097/CJI.0b013e318247a5e9
196. J.Karavitis, L.M.Hix, Y.H.Shi, R.F.Schultz, K.Khazaie, M.Zhang. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One 2012; 7:e46342; PMID:23029485; 10.1371/journal.pone.0046342
197. N.Obermajer, R.Muthuswamy, J.Lesnock, R.P.Edwards, P.Kalinski. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118:5498-505; PMID:21972293; 10.1182/blood-2011-07-365825
198. N.Obermajer, R.Muthuswamy, K.Odunsi, R.P.Edwards, P.Kalinski. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463-70; PMID:22025564; 10.1158/0008-5472.CAN-11-2449
199. P.Sinha, V.K.Clements, A.M.Fulton, S.Ostrand-Rosenberg. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; 10.1158/0008-5472.CAN-06-4174
200. X.Ma, D.Holt, N.Kundu, J.Reader, O.Goloubeva, Y.Take, A.M.Fulton. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013; 2:e22647; PMID:23482441; 10.4161/onci.22647
201. M.Sokolowska, L.Y.Chen, Y.Liu, A.Martinez-Anton, H.Y.Qi, C.Logun, S.Alsaaty, Y.H.Park, D.L.Kastner, J.J.Chae et al. Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages. J Immunol 2015; 194:5472-87; PMID:25917098; 10.4049/jimmunol.1401343
202. C.Antonopoulos, G.R.Dubyak. Chemotherapy engages multiple pathways leading to IL-1beta production by myeloid leukocytes. Oncoimmunology 2014; 3:e27499; PMID:24800164; 10.4161/onci.27499
203. L.Galluzzi, J.M.Bravo-San Pedro, I.Vitale, S.A.Aaronson, J.M.Abrams, D.Adam, E.S.Alnemri, L.Altucci, D.Andrews, M.Annicchiarico-Petruzzelli et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58-73; PMID:25236395; 10.1038/cdd.2014.137
204. L.Galluzzi, I.Vitale, J.M.Abrams, E.S.Alnemri, E.H.Baehrecke, M.V.Blagosklonny, T.M.Dawson, V.L.Dawson, W.S.El-Deiry, S.Fulda et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; 10.1038/cdd.2011.96
205. L.Galluzzi, J.M.Bravo-San Pedro, G.Kroemer. Organelle-specific initiation of cell death. Nat Cell Biol 2014; 16:728-36; PMID:25082195; 10.1038/ncb3005
206. F.Franchi, D.J.Angiolillo. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12:30-47; PMID:25286881; 10.1038/nrcardio.2014.156
207. X.Liao, P.Lochhead, R.Nishihara, T.Morikawa, A.Kuchiba, M.Yamauchi, Y.Imamura, Z.R.Qian, Y.Baba, K.Shima et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596-606; PMID:23094721; 10.1056/NEJMoa1207756
208. A.M.Algra, P.M.Rothwell. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13:518-27; PMID:22440112; 10.1016/S1470-2045(12)70112-2
209. D.A.Walsh, D.F.McWilliams. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10:581-92; PMID:24861185; 10.1038/nrrheum.2014.64
210. M.Fujita, G.Kohanbash, W.Fellows-Mayle, R.L.Hamilton, Y.Komohara, S.A.Decker, J.R.Ohlfest, H.Okada. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71:2664-74; PMID:21324923; 10.1158/0008-5472.CAN-10-3055
211. J.D.Veltman, M.E.Lambers, M.van Nimwegen, R.W.Hendriks, H.C.Hoogsteden, J.G.Aerts, J.P.Hegmans. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010; 10:464; PMID:20804550; 10.1186/1471-2407-10-464
212. H.E.Zeytin, A.C.Patel, C.J.Rogers, D.Canter, S.D.Hursting, J.Schlom, J.W.Greiner. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004; 64:3668-78; PMID:15150127; 10.1158/0008-5472.CAN-03-3878
213. N.Kundu, T.C.Walser, X.Ma, A.M.Fulton. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 2005; 54:981-7; PMID:15891886; 10.1007/s00262-005-0669-2
214. A.Kosaka, T.Ohkuri, H.Okada. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 2014; 63:847-57; PMID:24878890; 10.1007/s00262-014-1561-8
215. T.Hahn, I.Alvarez, J.J.Kobie, L.Ramanathapuram, S.Dial, A.Fulton, D.Besselsen, E.Walker, E.T.Akporiaye. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006; 118:2220-31; PMID:16331615; 10.1002/ijc.21616
216. L.M.Carlson, A.Rasmuson, H.Idborg, L.Segerstrom, P.J.Jakobsson, B.Sveinbjornsson, P.Kogner. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 2013; 34:1081-8; PMID:23349014; 10.1093/carcin/bgt009
217. M.Majumder, X.Xin, L.Liu, G.V.Girish, P.K.Lala. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci 2014; 105:1142-51; PMID:24981602; 10.1111/cas.12475
218. B.Ahn, G.Kohanbash, T.Ohkuri, A.Kosaka, X.Chen, M.Ikeura, T.C.Wang, H.Okada. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology 2015; 4:e1047581; PMID:26451324; 10.1080/2162402X.2015.1047581
219. S.Burdette-Radoux, C.E.Holmes, F.B.Khan, K.Dittus, K.M.Wilson, M.Wood. Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients without pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer. ASCO Meeting Abstracts 2013; 31:163
220. S.Burdette-Radoux, C.E.Holmes, F.B.Khan, K.Dittus, K.M.Wilson, M.E.Wood. Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients who fail to achieve pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer. ASCO Meeting Abstracts 2013; 31:e12000
221. J.W.Kim, J.L.Marte, M.Bilusic, N.K.Singh, C.R.Heery, R.A.Madan et al. Safety profile of poxviral vaccines: NCI experience. ASCO Meeting Abstracts 2013; 31:85
222. J.W.Kim, J.L.Marte, N.K.Singh, C.R.Heery, R.A.Madan, M.Pazdur et al. Safety profile of recombinant poxviral TRICOM vaccines. ASCO Meeting Abstracts 2013; 31:e16036
223. E.Ellebaek, L.Engell-Noerregaard, T.Z.Iversen, T.M.Froesig, S.Munir, S.R.Hadrup et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 2012; 61:1791-804; PMID:22426890; 10.1007/s00262-012-1242-4
224. K.J.af Forselles, J.Root, T.Clarke, D.Davey, K.Aughton, K.Dack, N.Pullen In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist. Br J Pharmacol 2011; 164:1847-56; PMID:21595651; 10.1111/j.1476-5381.2011.01495.x
225. M.A.Birrell, S.A.Maher, J.Buckley, N.Dale, S.Bonvini, K.Raemdonck, N.Pullen, M.A.Giembycz, M.G.Belvisi. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol 2013; 168:129-38; PMID:22747912; 10.1111/j.1476-5381.2012.02088.x
226. N.Kundu, X.Ma, D.Holt, O.Goloubeva, S.Ostrand-Rosenberg, A.M.Fulton. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009; 117:235-42; PMID:18792778; 10.1007/s10549-008-0180-5
227. M.Antonova, T.Wienecke, K.Maubach, E.Thomas, J.Olesen, M.Ashina. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain 2011; 12:551-9; PMID:21681585; 10.1007/s10194-011-0358-9
228. N.R.West, S.McCuaig, F.Franchini, F.Powrie. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 2015; 15:615-29; PMID:26358393; 10.1038/nri3896
229. H.E.Barker, J.T.Paget, A.A.Khan, K.J.Harrington. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 2015; 15:409-25; PMID:26105538; 10.1038/nrc3958
230. L.Zitvogel, L.Galluzzi, O.Kepp, M.J.Smyth, G.Kroemer. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; 10.1038/nri3845
231. M.Pickup, S.Novitskiy, H.L.Moses. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99; PMID:24132110; 10.1038/nrc3603
232. X.Chen, L.M.Wakefield, J.J.Oppenheim. Synergistic antitumor effects of a TGFbeta inhibitor and cyclophosphamide. Oncoimmunology 2014; 3:e28247; PMID:25050195; 10.4161/onci.28247
233. S.Lonning, J.Mannick, J.M.McPherson. Antibody targeting of TGF-beta in cancer patients. Curr Pharm Biotechnol 2011; 12:2176-89; PMID:21619535; 10.2174/138920111798808392
234. J.C.Morris, A.R.Tan, T.E.Olencki, G.I.Shapiro, B.J.Dezube, M.Reiss, F.J.Hsu, J.A.Berzofsky, D.P.Lawrence. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 2014; 9:e90353; PMID:24618589; 10.1371/journal.pone.0090353
235. M.K.Kashyap, D.Kumar, H.Jones, C.I.Amaya-Chanaga, M.Y.Choi, J.Melo-Cardenas, A.Ale-Ali, M.R.Kuhne, P.Sabbatini, L.J.Cohen et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 2015; 7:2809-22; PMID:26646452; 10.18632/oncotarget.6465.
236. M.O'Hayre, J.Vazquez-Prado, I.Kufareva, E.W.Stawiski, T.M.Handel, S.Seshagiri, J.S.Gutkind. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 2013; 13:412-24; PMID:23640210; 10.1038/nrc3521
237. L.Chen, D.B.Flies. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42; PMID:23470321; 10.1038/nri3405
238. C.Feig, J.O.Jones, M.Kraman, R.J.Wells, A.Deonarine, D.S.Chan, C.M.Connell, E.W.Roberts, Q.Zhao, O.L.Caballero et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110:20212-7; PMID:24277834; 10.1073/pnas.1320318110
239. M.Yan, N.Jene, D.Byrne, E.K.Millar, S.A.O'Toole, C.M.McNeil, G.J.Bates, A.L.Harris, A.H.Banham, R.L.Sutherland et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011; 13:R47; PMID:21521526; 10.1186/bcr2869.
240. B.Debnath, S.Xu, F.Grande, A.Garofalo, N.Neamati. Small molecule inhibitors of CXCR4. Theranostics 2013; 3:47-75; PMID:23382786; 10.7150/thno.5376
241. F.de Nigris, C.Schiano, T.Infante, C.Napoli. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov 2012; 7:251-64; PMID:22376154; 10.2174/157489212801820039
242. H.Deng, R.Liu, W.Ellmeier, S.Choe, D.Unutmaz, M.Burkhart, P.Di Marzio, S.Marmon, R.E.Sutton, C.M.Hill et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6; PMID:8649511; 10.1038/381661a0
243. Y.Feng, C.C.Broder, P.E.Kennedy, E.A.Berger. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7; PMID:8629022; 10.1126/science.272.5263.872
244. L.Zhang, Y.Huang, T.He, Y.Cao, D.D.Ho. HIV-1 subtype and second-receptor use. Nature 1996; 383:768; PMID:8892998; 10.1038/383768a0
245. A.Peled, O.Wald, J.Burger. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 2012; 21:341-53; PMID:22283809; 10.1517/13543784.2012.656197
246. S.M.Devine, N.Flomenberg, D.H.Vesole, J.Liesveld, D.Weisdorf, K.Badel, G.Calandra, J.F.DiPersio. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1095-102; PMID:15020611; 10.1200/JCO.2004.07.131
247. S.M.Devine, R.Vij, M.Rettig, L.Todt, K.McGlauchlen, N.Fisher, H.Devine, D.C.Link, G.Calandra, G.Bridger et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990-8; PMID:18426988; 10.1182/blood-2007-12-130179
248. A.K.Azab, J.M.Runnels, C.Pitsillides, A.S.Moreau, F.Azab, X.Leleu, X.Jia, R.Wright, B.Ospina, A.L.Carlson et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113:4341-51; PMID:19139079; 10.1182/blood-2008-10-186668
249. E.A.Sison, D.Magoon, L.Li, C.E.Annesley, R.E.Rau, D.Small, P.Brown. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget 2014; 5:8947-58; PMID:25333254; 10.18632/oncotarget.2407
250. S.N.Byrne, S.N.Sarchio. AMD3100 protects from UV-induced skin cancer. Oncoimmunology 2014; 3:e27562; PMID:24744978; 10.4161/onci.27562
251. B.S.Cho, Z.Zeng, H.Mu, Z.Wang, S.Konoplev, T.McQueen, M.Protopopova, J.Cortes, J.R.Marszalek, S.B.Peng et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 2015; 126:222-32; PMID:26031918; 10.1182/blood-2015-02-628677
252. J.D.Hainsworth, J.R.Mace, J.A.Reeves, E.J.Crane, O.Hamid, J.R.Stille et al. Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. ASCO Meeting Abstracts 2015; 33:4547
253. R.Salgia, R.W.Weaver, M.McCleod, J.R.Stille, S.B.Yan, S.Roberson et al. Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC). ASCO Meeting Abstracts 2015; 33:7567
254. J.R.Stille, A.Flynt, V.L.Peek, S.Gross, J.Keij, M.C.Connelly et al. CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts). ASCO Meeting Abstracts 2015; 33:e18558
255. J.J.Ziarek, Y.Liu, E.Smith, G.Zhang, F.C.Peterson, J.Chen, Y.Yu, Y.Chen, B.F.Volkman, R.Li. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction. Curr Top Med Chem 2012; 12:2727-40; PMID:23368099; 10.2174/1568026611212240003
256. Z.Liang, W.Zhan, A.Zhu, Y.Yoon, S.Lin, M.Sasaki, J.M.Klapproth, H.Yang, H.E.Grossniklaus, J.Xu et al. Development of a unique small molecule modulator of CXCR4. PLoS One 2012; 7:e34038; PMID:22485156; 10.1371/journal.pone.0034038
257. G.L.Gravina, A.Mancini, P.Muzi, L.Ventura, L.Biordi, E.Ricevuto, S.Pompili, C.Mattei, E.Di Cesare, E.A.Jannini et al. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate 2015; 75:1227-46; PMID:26073897; 10.1002/pros.23007
258. M.Gil, M.Seshadri, M.P.Komorowski, S.I.Abrams, D.Kozbor. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A 2013; 110:E1291-300; PMID:23509246; 10.1073/pnas.1220580110
259. A.Drenckhan, N.Kurschat, T.Dohrmann, N.Raabe, A.M.Koenig, U.Reichelt, J.T.Kaifi, J.R.Izbicki, S.J.Gros. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res 2013; 182:250-6; PMID:23117118; 10.1016/j.jss.2012.09.035
260. S.Hassan, M.Buchanan, K.Jahan, A.Aguilar-Mahecha, L.Gaboury, W.J.Muller, Y.Alsawafi, A.A.Mourskaia, P.M.Siegel, O.Salvucci et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011; 129:225-32; PMID:20830712; 10.1002/ijc.25665
261. S.Porvasnik, N.Sakamoto, S.Kusmartsev, E.Eruslanov, W.J.Kim, W.Cao, C.Urbanek, D.Wong, S.Goodison, C.J.Rosser. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69:1460-9; PMID:19588526; 10.1002/pros.21008
262. E.H.Huang, B.Singh, M.Cristofanilli, J.Gelovani, C.Wei, L.Vincent, K.R.Cook, A.Lucci. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155:231-6; PMID:19482312; 10.1016/j.jss.2008.06.044
263. E.A.Sison, D.Magoon, L.Li, C.E.Annesley, B.Romagnoli, G.J.Douglas, G.Tuffin, J.Zimmermann, P.Brown. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget 2015; 6:30902-18; PMID:26360610; 10.18632/oncotarget.5094
264. J.Xie The hedgehog's trick for escaping immunosurveillance: The molecular mechanisms driving myeloid-derived suppressor cell recruitment in hedgehog signaling-dependent tumors. Oncoimmunology 2014; 3:e29180; PMID:25054089; 10.4161/onci.29180
265. D.E.Sanford, B.A.Belt, R.Z.Panni, A.Mayer, A.D.Deshpande, D.Carpenter, J.B.Mitchem, S.M.Plambeck-Suess, L.A.Worley, B.D.Goetz et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013; 19:3404-15; PMID:23653148; 10.1158/1078-0432.CCR-13-0525
266. A.M.Lesokhin, T.M.Hohl, S.Kitano, C.Cortez, D.Hirschhorn-Cymerman, F.Avogadri, G.A.Rizzuto, J.J.Lazarus, E.G.Pamer, A.N.Houghton et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; 10.1158/0008-5472.CAN-11-1792
267. B.Z.Qian, J.Li, H.Zhang, T.Kitamura, J.Zhang, L.R.Campion, E.A.Kaiser, L.A.Snyder, J.W.Pollard. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5; PMID:21654748; 10.1038/nature10138
268. Y.Sato, K.Shimizu, J.Shinga, M.Hidaka, F.Kawano, K.Kakimi, S.Yamasaki, M.Asakura, S.I.Fujii. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. Oncoimmunology 2015; 4:e995541; PMID:25949922; 10.1080/2162402X.2014.995541
269. L.K.Spary, J.Salimu, J.P.Webber, A.Clayton, M.D.Mason, Z.Tabi. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology 2014; 3:e955331; PMID:25941611; 10.4161/21624011.2014.955331
270. T.Lanca, M.F.Costa, N.Goncalves-Sousa, M.Rei, A.R.Grosso, C.Penido, B.Silva-Santos. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol 2013; 190:6673-80; PMID:23686489; 10.4049/jimmunol.1300434
271. Y.Ma, S.R.Mattarollo, S.Adjemian, H.Yang, L.Aymeric, D.Hannani, J.P.Portela Catani, H.Duret, M.W.Teng, O.Kepp et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014; 74:436-45; PMID:24302580; 10.1158/0008-5472.CAN-13-1265
272. Y.Ma, S.Adjemian, L.Galluzzi, L.Zitvogel, G.Kroemer. Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. Oncoimmunology 2014; 3:e27663; PMID:24800170; 10.4161/onci.27663
273. A.Iannello, D.H.Raulet. Immunosurveillance of senescent cancer cells by natural killer cells. Oncoimmunology 2014; 3:e27616; PMID:24800169; 10.4161/onci.27616
274. M.K.Schwarz, T.N.Wells. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2002; 1:347-58; PMID:12120410; 10.1038/nrd795
275. J.Kalliomaki, N.Attal, B.Jonzon, F.W.Bach, K.Huizar, S.Ratcliffe, B.Eriksson, M.Janecki, A.Danilov, D.Bouhassira et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain 2013; 154:761-7; PMID:23523116; 10.1016/j.pain.2013.02.003
276. D.de Zeeuw, P.Bekker, E.Henkel, C.Hasslacher, I.Gouni-Berthold, H.Mehling, A.Potarca, V.Tesar, H.J.Heerspink, T.J.Schall. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 2015; 3:687-96; PMID:26268910; 10.1016/S2213-8587(15)00261-2
277. T.Sullivan, Z.Miao, D.J.Dairaghi, A.Krasinski, Y.Wang, B.N.Zhao, T.Baumgart, L.S.Ertl, A.Pennell, L.Seitz et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 2013; 305:F1288-97; PMID:23986513; 10.1152/ajprenal.00316.2013
278. T.J.Sullivan, Z.Miao, B.N.Zhao, L.S.Ertl, Y.Wang, A.Krasinski, M.J.Walters, J.P.Powers, D.J.Dairaghi, T.Baumgart et al. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 2013; 62:1623-32; PMID:23953944; 10.1016/j.metabol.2013.06.008
279. S.H.Min, Y.Wang, W.Gonsiorek, G.Anilkumar, J.Kozlowski, D.Lundell, J.S.Fine, E.P.Grant. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem Biophys Res Commun 2010; 391:1080-6; PMID:20004647; 10.1016/j.bbrc.2009.12.025
280. T.Dragic, V.Litwin, G.P.Allaway, S.R.Martin, Y.Huang, K.A.Nagashima, C.Cayanan, P.J.Maddon, R.A.Koup, J.P.Moore et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73; PMID:8649512; 10.1038/381667a0
281. G.Alkhatib, C.Combadiere, C.C.Broder, Y.Feng, P.E.Kennedy, P.M.Murphy, E.A.Berger. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8; PMID:8658171; 10.1126/science.272.5270.1955
282. E.Schlecker, A.Stojanovic, C.Eisen, C.Quack, C.S.Falk, V.Umansky, A.Cerwenka Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189:5602-11; PMID:23152559; 10.4049/jimmunol.1201018
283. M.C.Tan, P.S.Goedegebuure, B.A.Belt, B.Flaherty, N.Sankpal, W.E.Gillanders, T.J.Eberlein, C.S.Hsieh, D.C.Linehan. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182:1746-55; PMID:19155524; 10.4049/jimmunol.182.3.1746
284. P.Weitzenfeld, A.Ben-Baruch. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014; 352:36-53; PMID:24141062; 10.1016/j.canlet.2013.10.006
285. L.Ochoa-Callejero, L.Perez-Martinez, S.Rubio-Mediavilla, J.A.Oteo, A.Martinez, J.R.Blanco. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One 2013; 8:e53992; PMID:23326556; 10.1371/journal.pone.0053992
286. M.Velasco-Velazquez, X.Jiao, M.De La Fuente, T.G.Pestell, A.Ertel, M.P.Lisanti, R.G.Pestell. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72:3839-50; PMID:22637726; 10.1158/0008-5472.CAN-11-3917
287. C.Frankenberger, D.Rabe, R.Bainer, D.Sankarasharma, K.Chada, T.Krausz, Y.Gilad, L.Becker, M.R.Rosner. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages. Cancer Res 2015; 75:4063-73; PMID:26238785; 10.1158/0008-5472.CAN-14-3394
288. A.Chawla, A.V.Philips, G.Alatrash, E.Mittendorf. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3:e28325; PMID:24843833; 10.4161/onci.28325
289. A.Opar New HIV drug classes on the horizon. Nat Rev Drug Discov 2007; 6:258-9; PMID:17457997; 10.1038/nrd2294
290. G.Fatkenheuer, M.Nelson, A.Lazzarin, I.Konourina, A.I.Hoepelman, H.Lampiris, B.Hirschel, P.Tebas, F.Raffi, B.Trottier et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55; PMID:18832245; 10.1056/NEJMoa0803154
291. S.W.Choi, P.Reddy. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol 2014; 11:536-47; PMID:24958183; 10.1038/nrclinonc.2014.102
292. R.Reshef, S.M.Luger, E.O.Hexner, A.W.Loren, N.V.Frey, S.D.Nasta, S.C.Goldstein, E.A.Stadtmauer, J.Smith, S.Bailey et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367:135-45; PMID:22784116; 10.1056/NEJMoa1201248
293. H.J.Stellbrink. Novel compounds for the treatment of HIV type-1 infection. Antivir Chem Chemother 2009; 19:189-200; PMID:19483267; 10.1177/095632020901900502
294. D.M.Rotstein, S.D.Gabriel, N.Manser, L.Filonova, F.Padilla, S.Sankuratri, C.Ji, A.deRosier, M.Dioszegi, G.Heilek et al. Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett 2010; 20:3219-22; PMID:20457517; 10.1016/j.bmcl.2010.04.077
295. D.M.Rotstein, S.D.Gabriel, F.Makra, L.Filonova, S.Gleason, C.Brotherton-Pleiss, L.Q.Setti, A.Trejo-Martin, E.K.Lee, S.Sankuratri et al. Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett 2009; 19:5401-6; PMID:19674898; 10.1016/j.bmcl.2009.07.122
296. S.M.Pyonteck, L.Akkari, A.J.Schuhmacher, R.L.Bowman, L.Sevenich, D.F.Quail, O.C.Olson, M.L.Quick, J.T.Huse, V.Teijeiro et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72; PMID:24056773; 10.1038/nm.3337
297. B.Ruffell, L.M.Coussens. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015; 27:462-72; PMID:25858805; 10.1016/j.ccell.2015.02.015
298. D.G.DeNardo, D.J.Brennan, E.Rexhepaj, B.Ruffell, S.L.Shiao, S.F.Madden, W.M.Gallagher, N.Wadhwani, S.D.Keil, S.A.Junaid et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; 10.1158/2159-8274.CD-10-0028
299. M.J.Cavnar, R.P.DeMatteo. Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages. Oncoimmunology 2014; 3:e28463; PMID:25050212; 10.4161/onci.28463
300. S.Mok, J.Tsoi, R.C.Koya, S.Hu-Lieskovan, B.L.West, G.Bollag, T.G.Graeber, A.Ribas. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 2015; 15:356; PMID:25939769; 10.1186/s12885-015-1377-8
301. S.L.Shiao, B.Ruffell, D.G.DeNardo, B.A.Faddegon, C.C.Park, L.M.Coussens. TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res 2015; 3:518-25; PMID:25716473; 10.1158/2326-6066.CIR-14-0232
302. P.P.Patwardhan, O.Surriga, M.J.Beckman, E.de Stanchina, R.P.Dematteo, W.D.Tap, G.K.Schwartz. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res 2014; 20:3146-58; PMID:24718867; 10.1158/1078-0432.CCR-13-2576
303. M.Sluijter, T.C.van der Sluis, P.A.van der Velden, M.Versluis, B.L.West, S.H.van der Burg, T.van Hall. Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One 2014; 9:e104230; PMID:25110953; 10.1371/journal.pone.0104230
304. S.Mok, R.C.Koya, C.Tsui, J.Xu, L.Robert, L.Wu, T.G.Graeber, B.L.West, G.Bollag, A.Ribas. Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Res 2014; 74:153-61; PMID:24247719; 10.1158/0008-5472.CAN-13-1816
305. W.D.Tap, Z.A.Wainberg, S.P.Anthony, P.N.Ibrahim, C.Zhang, J.H.Healey, B.Chmielowski, A.P.Staddon, A.L.Cohn, G.I.Shapiro et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med 2015; 373:428-37; PMID:26222558; 10.1056/NEJMoa1411366
306. N.A.Butowski, H.Colman, J.F.De Groot, A.M.P.Omuro, L.Nayak, T.F.Cloughesy, A.Marimuthu, A.Perry, J.J.Phillips, B.West. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. ASCO Meeting Abstracts 2014; 32:2023
307. N.Butowski, H.Colman, J.F.De Groot, A.M.Omuro, L.Nayak, P.Y.Wen, T.F.Cloughesy, A.Marimuthu, S.Haidar, A.Perry et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 2015; PMID:26449250; 10.1093/neuonc/nov245
308. N.Sharma, R.Wesolowski, L.Reebel, M.B.Rodal, A.Peck, B.West, D.A.Karlin, A.Dowlati, M.H.Le, L.M.Coussens et al. A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32:3127
309. D.C.Strachan, B.Ruffell, Y.Oei, M.J.Bissell, L.M.Coussens, N.Pryer, D.Daniel. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013; 2:e26968; PMID:24498562; 10.4161/onci.26968
310. D.L.Moughon, H.He, S.Schokrpur, Z.K.Jiang, M.Yaqoob, J.David, C.Lin, M.L.Iruela-Arispe, O.Dorigo, L.Wu. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. Cancer Res 2015; 75:4742-52; PMID:26471360; 10.1158/0008-5472.CAN-14-3373
311. B.R.Achyut, A.Shankar, A.S.Iskander, R.Ara, K.Angara, P.Zeng, R.A.Knight, A.G.Scicli, A.S.Arbab. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. Cancer Lett 2015; 369:416-26; PMID:26404753; 10.1016/j.canlet.2015.09.004
312. L.Boulter, R.V.Guest, T.J.Kendall, D.H.Wilson, D.Wojtacha, A.J.Robson, R.A.Ridgway, K.Samuel, N.Van Rooijen, S.T.Barry et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest 2015; 125:1269-85; PMID:25689248; 10.1172/JCI76452
313. A.J.Garcia, M.Ruscetti, T.L.Arenzana, L.M.Tran, D.Bianci-Frias, E.Sybert, S.J.Priceman, L.Wu, P.S.Nelson, S.T.Smale et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 2014; 34:2017-28; PMID:24662052; 10.1128/MCB.00090-14
314. M.Ryder, M.Gild, T.M.Hohl, E.Pamer, J.Knauf, R.Ghossein, J.A.Joyce, J.A.Fagin. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One 2013; 8:e54302; PMID:23372702; 10.1371/journal.pone.0054302
315. Y.Komohara, H.Horlad, K.Ohnishi, Y.Fujiwara, B.Bai, T.Nakagawa, S.Suzu, H.Nakamura, J.Kuratsu, M.Takeya. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci 2012; 103:2165-72; PMID:22957741; 10.1111/cas.12015
316. J.Xu, J.Escamilla, S.Mok, J.David, S.Priceman, B.West, G.Bollag, W.McBride, L.Wu. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013; 73:2782-94; PMID:23418320; 10.1158/0008-5472.CAN-12-3981
317. N.Weizman, Y.Krelin, A.Shabtay-Orbach, M.Amit, Y.Binenbaum, R.J.Wong, Z.Gil. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014; 33:3812-9; PMID:23995783; 10.1038/onc.2013.357
318. S.J.Priceman, J.L.Sung, Z.Shaposhnik, J.B.Burton, A.X.Torres-Collado, D.L.Moughon, M.Johnson, A.J.Lusis, D.A.Cohen, M.L.Iruela-Arispe et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461-71; PMID:20008303; 10.1182/blood-2009-08-237412
319. H.Ohnuki, G.Tosato. Notch and TGFbeta: Functional partners facilitating tumor progression. Oncoimmunology 2014; 3:e29029; PMID:25114830; 10.4161/onci.29029
320. F.L.Liu, E.P.Mo, L.Yang, J.Du, H.S.Wang, H.Zhang, H.Kurihara, J.Xu, S.H.Cai. Autophagy is involved in TGF-beta1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in tumor microenvironment. Oncotarget 2015; PMID:26716641; 10.18632/oncotarget.6702
321. S.Kloss, N.Chambron, T.Gardlowski, L.Arseniev, J.Koch, R.Esser, W.Glienke, O.Seitz, U.Köhl. Increased sMICA and TGFbeta levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology 2015; 4:e1055993; PMID:26451327; 10.1080/2162402X.2015.1055993
322. M.J.Anderton, H.R.Mellor, A.Bell, C.Sadler, M.Pass, S.Powell, S.J.Steele, R.R.Roberts, A.Heier. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 2011; 39:916-24; PMID:21859884; 10.1177/0192623311416259
323. L.Bueno, D.P.de Alwis, C.Pitou, J.Yingling, M.Lahn, S.Glatt, I.F.Trocóniz. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008; 44:142-50; PMID:18039567; 10.1016/j.ejca.2007.10.008
324. N.E.Bhola, J.M.Balko, T.C.Dugger, M.G.Kuba, V.Sanchez, M.Sanders, J.Stanford, R.S.Cook, C.L.Arteaga. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013; 123:1348-58; PMID:23391723; 10.1172/JCI65416
325. J.H.Yoon, S.M.Jung, S.H.Park, M.Kato, T.Yamashita, I.K.Lee, K.Sudo, S.Nakae, J.S.Han, O.H.Kim et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol Med 2013; 5:1720-39; PMID:24127404; 10.1002/emmm.201302524
326. S.Herbertz, J.S.Sawyer, A.J.Stauber, I.Gueorguieva, K.E.Driscoll, S.T.Estrem, A.L.Cleverly, D.Desaiah, S.C.Guba, K.A.Benhadji et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015; 9:4479-99; PMID:26309397; 10.2147/DDDT.S86621
327. Y.Fujiwara, H.Nokihara, Y.Yamada, N.Yamamoto, K.Sunami, H.Utsumi, H.Asou, O.TakahashI, K.Ogasawara, I.Gueorguieva et al. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2015; 76:1143-52; PMID:26526984; 10.1007/s00280-015-2895-4
328. J.Rodon, M.A.Carducci, J.M.Sepulveda, A.Azaro, E.Calvo, J.Seoane, I.Brana, E.Sicart, I.Gueorguieva, A.Cleverly et al. Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor, LY2157299 monohydrate (LY). ASCO Meeting Abstracts 2013; 31:2016
329. J.Rodon, M.Carducci, J.M.Sepulveda-Sanchez, A.Azaro, E.Calvo, J.Seoane, I.Braña, E.Sicart, I.Gueorguieva, A.Cleverly et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015; 33:357-70; PMID:25529192; 10.1007/s10637-014-0192-4
330. J.Rodon, M.A.Carducci, J.M.Sepulveda-Sanchez, A.Azaro, E.Calvo, J.Seoane, I.Braña, E.Sicart, I.Gueorguieva, A.L.Cleverly et al. First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res 2015; 21:553-60; PMID:25424852; 10.1158/1078-0432.CCR-14-1380
331. R.J.Kovacs, G.Maldonado, A.Azaro, M.S.Fernandez, F.L.Romero, J.M.Sepulveda-Sanchez, M.Corretti, M.Carducci, M.Dolan, I.Gueorguieva et al. Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol 2015; 15:309-23; PMID:25488804; 10.1007/s12012-014-9297-4
332. C.Suarez, J.Rodon, A.Desjardins, P.A.J.Forsyth, I.Gueorguieva, A.Cleverly et al. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. ASCO Meeting Abstracts 2013; 31:2039
333. M.Kozloff, R.Carbonero, T.Nadal, I.Gueorguieva, A.Cleverly, D.Desaiah et al. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer. ASCO Meeting Abstracts 2013; 31:2563
334. A.A.Brandes, A.F.Carpentier, S.Kesari, J.Sepulveda, H.Wheeler, O.L.Chinot et al. A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. ASCO Meeting Abstracts 2015; 33:2014
335. A.F.Carpentier, A.A.Brandes, S.Kesari, J.M.Sepulveda, H.Wheeler, O.L.Chinot et al. Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression. ASCO Meeting Abstracts 2013; 31:2061
336. S.J.Faivre, A.Santoro, R.K.Kelley, P.Merle, E.Gane, J.-Y.Douillard et al. Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts 2013; 31:4118
337. D.R.Sharda, S.Yu, M.Ray, M.L.Squadrito, M.De Palma, T.A.Wynn, S.M.MorrisJr, P.A.Hankey. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol 2011; 187:2181-92; PMID:21810604; 10.4049/jimmunol.1003460
338. A.Chaudhuri. Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling. Front Immunol 2014; 5:546; PMID:25400637; 10.3389/fimmu.2014.00546
339. L.M.Thorpe, H.Yuzugullu, J.J.Zhao. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015; 15:7-24; PMID:25533673; 10.1038/nrc3860
340. D.A.Fruman, C.Rommel. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13:140-56; PMID:24481312; 10.1038/nrd4204
341. J.Rodon, R.Dienstmann, V.Serra, J.Tabernero. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10:143-53; PMID:23400000; 10.1038/nrclinonc.2013.10
342. A.K.Gopal, B.S.Kahl, S.de Vos, N.D.Wagner-Johnston, S.J.Schuster, W.J.Jurczak, I.W.Flinn, C.R.Flowers, P.Martin, A.Viardot, I.W.Flinn, C.R.Flowers, P.Martin, A.Viardot et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370:1008-18; PMID:24450858; 10.1056/NEJMoa1314583
343. R.R.Furman, J.P.Sharman, S.E.Coutre, B.D.Cheson, J.M.Pagel, P.Hillmen, J.C.Barrientos, A.D.Zelenetz, T.J.Kipps, I.Flinn et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370:997-1007; PMID:24450857; 10.1056/NEJMoa1315226
344. K.Ali, D.R.Soond, R.Pineiro, T.Hagemann, W.Pearce, E.L.Lim, H.Bouabe, C.L.Scudamore, T.Hancox, H.Maecker et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014; 510:407-11; PMID:24919154; 10.1038/nature13444
345. H.Fu, M.Kishore, B.Gittens, G.Wang, D.Coe, I.Komarowska, E.Infante, A.J.Ridley, D.Cooper, M.Perretti et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nat Commun 2014; 5:3436; PMID:24625653; 10.1038/ncomms4436
346. M.C.Schmid, C.J.Avraamides, H.C.Dippold, I.Franco, P.Foubert, L.G.Ellies, L.M.Acevedo, J.R.Manglicmot, X.Song, W.Wrasidlo et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011; 19:715-27; PMID:21665146; 10.1016/j.ccr.2011.04.016
347. A.Shah, A.Mangaonkar. Idelalisib: A Novel PI3Kdelta Inhibitor for Chronic Lymphocytic Leukemia. Ann Pharmacother 2015; 49:1162-70; PMID:26185276; 10.1177/1060028015594813
348. C.Y.Cheah, L.J.Nastoupil, S.S.Neelapu, S.G.Forbes, Y.Oki, N.H.Fowler. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 2015; 125:3357-9; PMID:25999447; 10.1182/blood-2015-03-633156
349. Y.G.Hewett, D.Uprety, B.K.Shah. Idelalisib- a PI3Kdelta targeting agent for B-cell malignancies. J Oncol Pharm Pract 2016; 22:284-8; PMID:25712626; 10.1177/1078155215572933
350. B.S.Kahl, S.E.Spurgeon, R.R.Furman, I.W.Flinn, S.E.Coutre, J.R.Brown, D.M.Benson, J.C.Byrd, S.Peterman, Y.Cho et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123:3398-405; PMID:24615778; 10.1182/blood-2013-11-537555
351. J.R.Brown, J.C.Byrd, S.E.Coutre, D.M.Benson, I.W.Flinn, N.D.Wagner-Johnston, S.E.Spurgeon, B.S.Kahl, C.Bello, H.K.Webb et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123:3390-7; PMID:24615777; 10.1182/blood-2013-11-535047
352. I.W.Flinn, B.S.Kahl, J.P.Leonard, R.R.Furman, J.R.Brown, J.C.Byrd, N.D.Wagner-Johnston, S.E.Coutre, D.M.Benson, S.Peterman et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123:3406-13; PMID:24615776; 10.1182/blood-2013-11-538546
353. A.K.Sikalidis. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res 2015; 21:9-17; PMID:25351939; 10.1007/s12253-014-9860-0
354. P.C.Rodriguez, D.G.Quiceno, J.Zabaleta, B.Ortiz, A.H.Zea, M.B.Piazuelo, A.Delgado, P.Correa, J.Brayer, E.M.Sotomayor et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49; PMID:15313928; 10.1158/0008-5472.CAN-04-0465
355. V.Bronte, P.Zanovello. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; 10.1038/nri1668
356. C.Bogdan. Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol 2015; 36:161-78; PMID:25687683; 10.1016/j.it.2015.01.003
357. P.Serafini. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 2013; 57:172-84; PMID:24203443; 10.1007/s12026-013-8455-2
358. B.Molon, S.Ugel, F.Del Pozzo, C.Soldani, S.Zilio, D.Avella, A.De Palma, P.Mauri, A.Monegal, M.Rescigno et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62; PMID:21930770; 10.1084/jem.20101956
359. G.Gallina, L.Dolcetti, P.Serafini, C.De Santo, I.Marigo, M.P.Colombo, G.Basso, F.Brombacher, I.Borrello, P.Zanovello et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-90; PMID:17016559; 10.1172/JCI28828
360. M.C.Van Zandt, D.L.Whitehouse, A.Golebiowski, M.K.Ji, M.Zhang, R.P.Beckett, G.E.Jagdmann, T.R.Ryder, R.Sheeler, M.Andreoli et al. Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury. J Med Chem 2013; 56:2568-80; PMID:23472952; 10.1021/jm400014c
361. C.De Santo, P.Serafini, I.Marigo, L.Dolcetti, M.Bolla, P.Del Soldato, C.Melani, C.Guiducci, M.P.Colombo, M.Iezzi et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005; 102:4185-90; PMID:15753302; 10.1073/pnas.0409783102
362. A.Bratasz, N.M.Weir, N.L.Parinandi, J.L.Zweier, R.Sridhar, L.J.Ignarro, P.Kuppusamy Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A 2006; 103:3914-9; PMID:16497833; 10.1073/pnas.0511250103
363. G.H.Chu, B.Le Bourdonnec, M.Gu, C.W.Ajello, L.K.Leister, I.Sellitto, J.A.Cassel, P.A.Tuthill, H.O' Hare, R.N.Dehaven et al. Design and Synthesis of Imidazopyrimidine Derivatives as Potent iNOS Dimerization Inhibitors. Open Med Chem J 2009; 3:8-13; PMID:19966921; 10.2174/1874104500903010008
364. P.Serafini, K.Meckel, M.Kelso, K.Noonan, J.Califano, W.Koch, L.Dolcetti, V.Bronte, I.Borrello. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; 10.1084/jem.20061104
365. J.A.Califano, Z.Khan, K.A.Noonan, L.Rudraraju, Z.Zhang, H.Wang, S.Goodman, C.G.Gourin, P.K.Ha, C.Fakhry et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:30-8; PMID:25564570; 10.1158/1078-0432.CCR-14-1716
366. D.T.Weed, J.L.Vella, I.M.Reis, A.C.De la Fuente, C.Gomez, Z.Sargi, R.Nazarian, J.Califano, I.Borrello, P.Serafini. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:39-48; PMID:25320361; 10.1158/1078-0432.CCR-14-1711
367. M.Semeraro, L.Galluzzi. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; 10.4161/onci.28386
368. S.V.Frye, M.R.Arkin, C.H.Arrowsmith, P.J.Conn, M.A.Glicksman, E.A.Hull-Ryde, B.S.Slusher. Tackling reproducibility in academic preclinical drug discovery. Nat Rev Drug Discov 2015; 14:733-4; PMID:26388229; 10.1038/nrd4737
369. H.Gharwan, H.Groninger. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13:209-27; PMID:26718105; 10.1038/nrclinonc.2015.213
370. D.E.Frail, M.Brady, K.J.Escott, A.Holt, H.J.Sanganee, M.N.Pangalos, C.Watkins, C.D.Wegner. Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat Rev Drug Discov 2015; 14:833-41; PMID:26585533; 10.1038/nrd4707